Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Sanofi Genzyme declines opt-in on development and commercialization of lumasiran

March 13, 2018

Diamyd Medical offers update from DIAGNODE-1 study of Diamyd diabetes vaccine

March 12, 2018

Arrowhead opens enrollment in phase I study of ARO-AAT

March 12, 2018

Caladrius Biosciences announces interim results from phase II trial of CLBS-03 in type 1 diabetes

March 9, 2018

FDA accepts NDA for TX-001-HR

March 9, 2018

Medicure to commercialize Zydus Cadila's pitavastatin in U.S.

March 8, 2018

Arena Pharmaceuticals patents new 5-HT2C receptor agonists

March 8, 2018

Rigel Pharmaceuticals patents novel AMPK activators

March 7, 2018

Ligand grants Roivant rights to glucagon receptor antagonist LGD-6972

March 7, 2018

Takeda applies for approval of relugolix for uterine fibrosis in Japan

March 7, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...